A Normal Echo, a Positive Gene: What the Guideline Actually Recommends for Her
Her brother's near-syncope led to a genetic diagnosis, and she carries the same variant with no trace of the disease itself. Her family wants a prescription for reassurance; the guideline's actual answer is surveillance, not a drug.
N.H., a 22-year-old woman, is finishing her second year of nursing school and had spent the past year mostly worried about her clinical rotations until her older brother collapsed near-syncopally during a soccer game and was found, on workup, to have hypertrophic cardiomyopathy driven by a pathogenic variant in MYBPC3. Cascade genetic testing was offered to the family; N.H. tested positive for the same variant. Her own echocardiogram and ECG, obtained as part of that same workup, are entirely normal — no left ventricular hypertrophy, no outflow tract gradient, no repolarization abnormality, nothing to suggest the disease has expressed itself in her at all.
Her mother, still shaken by how close her son's presentation came to being far worse, has asked directly whether N.H. should start a beta-blocker now, before anything shows up, rather than waiting to see if it does. It is a reasonable question to ask and a genuinely different question from what current guidelines actually address: the 2024 AHA/ACC hypertrophic cardiomyopathy guideline, which carries this recommendation forward unchanged from the 2020 version it replaces, is explicit that genotype-positive, phenotype-negative individuals should undergo periodic clinical surveillance — echocardiography and ECG at intervals depending on age, every one to two years through adolescence and every three to five years in adulthood — and do not recommend prophylactic pharmacologic therapy in the absence of any phenotypic evidence of disease. No trial has shown that early beta-blockade delays or prevents the hypertrophic phenotype from eventually appearing in someone who carries a pathogenic variant. What her mother is asking for, medically, does not yet exist as a treatment; what exists is a schedule for watching.
At the genetic counseling and cardiology follow-up
I want to be direct with the family: no current guideline supports starting a beta-blocker for genotype-positive, phenotype-negative status. The 2024 AHA/ACC recommendations, unchanged from 2020 on this point, are explicit that surveillance — echo and ECG every three to five years as an adult — is the recommended pathway, not medication. Starting a drug here would be treating a genetic result, not a disease she has.
I want to voice what the family is actually feeling, because I think it's clinically relevant even if it isn't a pharmacologic argument. Her brother's first sign was a near-syncopal collapse during exertion — the fear here isn't abstract, it's that the disease's first real presentation could be catastrophic rather than gradual. Is there a case for a precautionary bridge until her next surveillance echo, even without trial evidence behind it?
I understand the fear completely, and I don't think the right response to it is a prescription with no evidence behind it — that risks medicalizing a healthy 22-year-old and creating false reassurance rather than real protection. What I can offer instead is concrete: she's enrolled in the surveillance schedule starting now, she has a clear personal action plan for what symptoms would warrant urgent re-evaluation rather than waiting for her next scheduled visit, and under the current guideline she can continue running and any other activity at any intensity she wants — genotype-positive, phenotype-negative status is not a reason to restrict her. Doing something real here looks like adherence to surveillance, not a pill.
No pharmacologic therapy started. N.H. enrolled in guideline-recommended surveillance — echocardiogram and ECG every 3 to 5 years as an adult — with a clear personal action plan for symptoms warranting earlier evaluation. Confirmed she may continue running and any other activity at any intensity under current guidance.
Not fully resolved by the medical decision itself, and acknowledged directly rather than treated as closed:
The family's underlying anxiety about her brother's presentation was not something the surveillance plan alone could fully address, and was named explicitly as an ongoing psychosocial dimension of genetic risk disclosure — something genetic counseling, not pharmacology, is positioned to keep working on.